Treatment of Small Vessel Disease With the Paclitaxel Drug‐Eluting Balloon: 6‐Month Angiographic and 1‐Year Clinical Outcomes of the Spanish Multicenter Registry

Abstract

The use of this PEB for the treatment of SMD provides excellent 1-year outcomes with only 4.8% MACE. The need for a bailout BMS was a strong predictor of MACE and TLR.